ArdorComm Media Group

Friday, February 27, 2026 4:02 PM

Public Health

AIIMS study reveals high prevalence of catheter-related infections in Indian hospitals

A nationwide study led by the All India Institute of Medical Sciences (AIIMS), New Delhi, has revealed that bloodstream infections linked to catheter use are widespread in intensive care units (ICUs) across India, with many cases caused by highly drug-resistant microbes. These hospital-acquired infections, known as Central Line-Associated Bloodstream Infections (CLABSI), occur when a catheter inserted into a large vein becomes contaminated. According to estimates published in The Lancet Global Health, Indian ICUs report nearly nine infection events for every 1,000 days a central line remains in use. The AIIMS-led team analysed seven years of data collected by the Indian Healthcare-Associated Infections (HAI) surveillance network, spanning 200 ICUs across 54 hospitals. Between May 2017 and April 2024, the network recorded 8,629 confirmed CLABSI cases, covering more than 3 million patient-days and nearly 1 million central line-days. The pooled CLABSI rate was found to be 8.83 per 1,000 central line-days. The study also observed a spike in infection rates during 2020–21, coinciding with the COVID-19 pandemic. Researchers attributed this surge to overburdened ICUs, staff shortages, and lapses in infection prevention practices. Experts stressed that while CLABSI is preventable, establishing systematic infection surveillance and prevention programs requires significant resources—a major challenge for low- and middle-income countries like India. Nevertheless, the findings mark the first large-scale, standardised surveillance report on CLABSI in India, offering a foundation for healthcare systems to adopt quality improvement measures. Source: PTI Photo Credit: AFP  

AIIMS study reveals high prevalence of catheter-related infections in Indian hospitals Read More »

IISc Study Warns of Bird Flu Strain’s Rising Threat to Humans

Researchers at the Indian Institute of Science (IISc) have raised concerns that the currently circulating H5N1 bird flu strain could be evolving to pose a greater risk to humans. The team, led by Kesavardhana Sannula from the Department of Biochemistry, found that the 2.3.4.4b clade of H5N1 carries genetic mutations similar to those seen in past pandemic influenza strains, enhancing its ability to adapt to human hosts. The study revealed that viruses capable of infecting foxes may have a higher human adaptation potential than those infecting cattle — a surprising finding. H5N1, first detected in birds about 30 years ago, has since caused sporadic human infections and widespread fatalities in birds and mammals, making it a panzootic concern. Using computational analysis of thousands of protein sequences from birds, mammals, and human influenza viruses, the researchers identified mutations concentrated in the viral polymerase complex (PA, PB2), nucleoproteins, and haemagglutinin (HA) proteins — key elements that could aid the virus in crossing the species barrier. The findings underscore the need for heightened surveillance and preparedness to mitigate potential outbreaks. Source: Indian Express

IISc Study Warns of Bird Flu Strain’s Rising Threat to Humans Read More »

Breakthrough in Understanding Childhood Immunity to Strep A Could Accelerate Vaccine Development

A team of scientists has uncovered how young children naturally build immunity against Group A Streptococcus (Strep A), a bacterial infection responsible for up to half a million deaths worldwide each year. The finding could significantly speed up the creation of a life-saving vaccine. Strep A is a common bacterium that can cause mild illnesses like sore throat and skin infections, but in severe cases, it can trigger life-threatening diseases. While deaths from Strep A are rare in wealthier nations, outbreaks can be devastating. In late 2022, a surge in cases across the UK and Europe claimed hundreds of lives, including those of many children. The burden is far greater in low- and middle-income countries, where thousands die annually from the infection. Researchers from the University of Sheffield, working with the Medical Research Council (MRC) Unit The Gambia at the London School of Hygiene and Tropical Medicine, tracked how Gambian children acquire natural immunity. Published in Nature Medicine, the study identified specific antibodies linked to protection from Strep A, marking a crucial step toward vaccine design. The team observed that babies are born with some immunity passed down from their mothers, but this protection fades quickly. Young children, however, develop robust antibody responses to different components of the bacteria after repeated exposure. This discovery pinpoints a key window for immune development, which could guide more effective vaccination strategies. Lead researcher Dr. Alex Keeley said this is the first time scientists have seen in humans how antibodies generated through vaccination might prevent Strep A infections. Gambian scientist Fatouamta Camara described the infection’s “devastating burden” on communities and expressed hope that a vaccine could break the cycle of illness and socio-economic hardship. The research was a collaboration between Sheffield’s Florey Institute of Infection and the GSK Vaccine Institute for Global Health. Professor Thushan de Silva, who co-directed the study, emphasised the importance of cross-institutional efforts in delivering impactful global health research. Source: PTI

Breakthrough in Understanding Childhood Immunity to Strep A Could Accelerate Vaccine Development Read More »

WHO Urges Boost in TB Research and Innovation to Tackle High Burden in South-East Asia

The World Health Organization (WHO) has issued an urgent call to enhance research, innovation, and regional cooperation to eliminate tuberculosis (TB) in the South-East Asia region — a region that continues to carry nearly half of the global TB burden. Speaking at the launch of a three-day virtual workshop focused on advancing TB research and innovation, Dr. Catharina Boehme, Officer-in-Charge for WHO South-East Asia, emphasized that in 2023 alone, the region saw nearly 5 million new TB cases and around 600,000 related deaths. The workshop brings together national TB programme leaders, scientists, civil society members, and global partners to push forward efforts aligned with the WHO’s End TB Strategy. The Need for Urgency and Collaboration Dr. Boehme highlighted that ending TB demands the rapid adoption of new tools, diagnostics, and treatments — and, more importantly, equitable and timely access to these innovations. “Collaboration is key to scaling up impact and ensuring that no one is left behind,” she stated. Despite a post-COVID-19 rebound in TB case detection in 2023, current progress is falling short of the End TB Strategy’s 2030 goals: a 90% drop in TB-related deaths and an 80% decline in incidence compared to 2015. Alarmingly, TB has returned as the world’s leading cause of death from a single infectious disease, with its effects disproportionately hitting the poorest and most vulnerable communities. In South-East Asia, between 30% and 80% of TB-affected households experience catastrophic healthcare expenses, pointing to the urgent need for inclusive, people-first approaches and stronger social protection systems. Signs of Progress Amidst Challenges Still, there are signs of advancement. In 2023, the region recorded 3.8 million new or relapsed TB cases, with an 89% treatment success rate among those who began treatment in 2022. The number of undiagnosed cases was significantly reduced — down to 22% from 44% in 2020. Countries are increasingly adopting technology-driven solutions such as artificial intelligence for detecting TB, digital adherence tools to monitor treatment, and direct benefit transfers to ease patients’ financial burdens. These innovations are being powered by strong political will and national commitment. Several countries have also expanded research efforts. Bangladesh has concluded a national patient cost survey, while India’s RATIONS study provided valuable insights on the role of nutrition in TB prevention and recovery. Nepal’s “TB-Free Pallika” initiative and Myanmar’s multisectoral coordination model are examples of community-led innovations that prioritize vulnerable populations. According to WHO, over 3,000 TB-related research papers were published by South-East Asian countries in the past six years, with 60% being original research. However, the challenge lies in transforming these findings into action, as knowledge gaps and lack of collaborative platforms hinder broader impact. Strengthening Regional and Global Coordination The workshop will also focus on building stronger South-South collaboration, vaccine readiness, use of digital tools for patient care, and tackling vaccine hesitancy. Discussions will revolve around aligning regulatory frameworks, improving knowledge-sharing platforms, and setting research priorities that address underlying drivers of TB — such as malnutrition and climate-related risks. Dr. Boehme noted the growing threat posed by drug-resistant TB and emphasized the importance of ensuring that scientific progress benefits everyone equally. “Access to new vaccines, medicines, and diagnostics must be equitable. Reaching underserved communities through proactive case-finding and offering socio-economic support is essential in mitigating the financial toll of TB,” she concluded. Source: PTI Photo Credit: Getty Images

WHO Urges Boost in TB Research and Innovation to Tackle High Burden in South-East Asia Read More »

India Records Over 7,000 Suspected Heatstroke Cases and 14 Confirmed Deaths Amid Rising Temperatures

Ardorcomm news

Between March 1 and June 24, 2025, India recorded 7,192 suspected cases of heatstroke and 14 confirmed deaths due to extreme heat, according to data obtained by PTI through the Right to Information (RTI) Act. The information, provided by the National Centre for Disease Control (NCDC), points to a growing public health concern amid soaring temperatures, as India experiences one of its hottest years on record since 1901. Majority of Heatstroke Cases Reported in May May proved to be the most critical month, with 2,962 suspected cases and three confirmed deaths. In April, there were 2,140 suspected cases and six confirmed fatalities, while March saw 705 cases and two deaths. Up to June 24, June added another 1,385 suspected cases and three confirmed fatalities. Andhra Pradesh emerged as the worst-hit state, reporting 4,055 suspected cases — more than half the national total during the period. Other significantly affected states included Rajasthan (373 cases), Odisha (350), Telangana (348), and Madhya Pradesh (297). Gaps in Death Reporting Highlight Systemic Flaws Despite the high number of suspected cases, many states, including those with hundreds of reported incidents, recorded few or no confirmed deaths. Maharashtra and Uttarakhand topped the list of confirmed fatalities, each reporting three deaths. Telangana, Odisha, Tamil Nadu, Jharkhand, Uttar Pradesh, and West Bengal each reported one. Experts and officials say the actual toll is likely much higher than reported due to systemic shortcomings in data collection and diagnosis. NCDC’s figures are based on reports from hospitals under the Integrated Disease Surveillance Programme (IDSP), leaving out cases that go untreated or undiagnosed, especially those occurring outside medical facilities. A health ministry official, speaking anonymously, acknowledged these limitations: “We only capture a fraction of real cases. Many deaths go unclassified due to lack of capacity, staff, and timely reporting in hospitals.” Inconsistent Records Across Agencies India’s fragmented approach to tracking heat-related illnesses was further exposed in a PTI investigation. For the 2015–2022 period, three government agencies reported vastly different numbers: NCDC cited 3,812 heat-related deaths, the National Crime Records Bureau (NCRB) recorded 8,171, and the India Meteorological Department (IMD) listed 3,436. Discrepancies are further worsened by states failing to provide complete or timely data. In previous years, Delhi, Uttar Pradesh, Punjab, Haryana, Bihar, Karnataka, Kerala, Chhattisgarh, and West Bengal have all been inconsistent in their reporting, with some reportedly underreporting deaths to avoid paying compensation. Heat-Related Deaths Often Misclassified Abhiyant Tiwari, Climate Resilience and Health Lead at NRDC India, emphasized the difficulty of accurately linking deaths to heat exposure. “Many are recorded as heart attacks or other conditions. To understand the true impact, we must look at excess mortality during heatwaves,” he said. Soumya Swaminathan, advisor to the Health Ministry, echoed the call for reform. “We need stronger death certification and reporting systems. Reliable data is essential for shaping effective climate and health policies,” she noted. As climate change intensifies the frequency and severity of heatwaves, the lack of a unified, robust national surveillance system remains a serious barrier to India’s readiness and response. Source: Economic Times  

India Records Over 7,000 Suspected Heatstroke Cases and 14 Confirmed Deaths Amid Rising Temperatures Read More »

ICMR Opens Door for Commercial Production of Next-Gen Malaria Vaccine

Ardorcomm news

The Indian Council of Medical Research (ICMR) has announced a major step forward in the fight against malaria by inviting expressions of interest (EoI) from eligible companies and manufacturers for the commercial production of a breakthrough malaria vaccine, AdFalciVax. Developed by the ICMR’s Regional Medical Research Centre in Bhubaneswar, this recombinant chimeric multi-stage vaccine targets Plasmodium falciparum, the deadliest malaria parasite, offering both individual protection and reduced community transmission. Pre-clinical validation of the vaccine technology was carried out in collaboration with ICMR-NIMR (National Institute of Malaria Research), other ICMR institutes, and the National Institute of Immunology in Delhi, which operates under the Department of Biotechnology. ICMR-RMRCBB will provide technical know-how and hands-on support throughout the vaccine production process to ensure a smooth and efficient pathway to commercialisation. Furthermore, ICMR’s team of seasoned scientists will assist in product development, study design, protocol development, data and results analysis, efficacy and safety assessments, and necessary improvements, based on mutual agreement with the collaborating partner. This initiative marks a significant stride in India’s effort to eliminate malaria through indigenous innovation and collaborative biotech development. Source: PTI

ICMR Opens Door for Commercial Production of Next-Gen Malaria Vaccine Read More »

India Nears Completion of Phase-3 Trials for Indigenous Dengue Vaccine: ICMR

India is on the cusp of a major public health milestone, with nearly 8,000 out of a targeted 10,000 participants already enrolled in Phase-3 clinical trials of the country’s first homegrown dengue vaccine, as per the Indian Council of Medical Research (ICMR). Dr. Manoj Murhekar, Director of ICMR’s National Institute of Epidemiology in Chennai, confirmed the progress in an interaction with The Hindu. The large-scale trials, which are being conducted at 20 different centres across the country, are testing the efficacy of DengiAll, a tetravalent vaccine developed by Panacea Biotec. This formulation aims to provide protection against all four known dengue virus serotypes that co-circulate in various parts of India. “An effective vaccine must be able to offer strong immunity against all four strains,” Dr. Murhekar emphasized. The ICMR is the primary funder of the project, with Panacea Biotec offering partial financial and technical support. Once vaccinated, participants will be monitored for a period of two years at locations including Delhi, Hyderabad, Pune, and Chennai. Currently, there is no approved vaccine or antiviral treatment for dengue in India, despite the disease being a recurring and widespread health issue. India remains among the top 30 countries most affected by dengue, according to the World Health Organization (WHO). By the end of 2023, over 129 countries had reported cases of dengue globally. The candidate vaccine, DengiAll, is derived from the TV003/TV005 tetravalent strain originally created by the U.S.-based National Institutes of Health. Panacea Biotec is one of three Indian firms granted access to the strain and has advanced furthest in the development process. The company completed early-stage (Phase-1 and 2) trials in 2018–19, which delivered encouraging results. It also holds a process patent for its unique formulation. The Union Health Ministry highlighted that the first participant in the Phase-3 trial received a dose at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in Rohtak last year. Dengue poses a significant health threat in India. Although 75–80% of infections are asymptomatic, individuals can still spread the virus via Aedes mosquito bites. Among symptomatic cases—comprising about 20–25%—children face an elevated risk of severe outcomes, including hospitalization and death. In adults, the disease can escalate into life-threatening conditions such as dengue hemorrhagic fever and dengue shock syndrome. The challenge of controlling the virus is compounded by the presence of four distinct serotypes, each offering limited cross-immunity, making repeated infections common. With the success of this trial, India could soon have its first domestically developed and licensed dengue vaccine, marking a crucial step forward in the country’s fight against vector-borne diseases. Source: The Hindu  

India Nears Completion of Phase-3 Trials for Indigenous Dengue Vaccine: ICMR Read More »

India May Face Over 1.6 Million Gastric Cancer Cases, Global Study Warns

A new international study published in Nature Medicine has sounded the alarm over a possible surge in gastric cancer cases, predicting that more than 15 million individuals born between 2008 and 2017 could develop the disease globally during their lifetime. India is projected to bear a significant burden, second only to China, with an estimated 1.6 million cases if current prevention efforts remain unchanged. The research, led by the International Agency for Research on Cancer (IARC), the cancer research wing of the World Health Organization, used global cancer incidence data from GLOBOCAN 2022 along with UN demographic forecasts. It found that nearly two-thirds of future gastric cancer cases will likely emerge in Asia, with India and China alone expected to contribute about 6.5 million new diagnoses. A key finding of the study highlights that 76% of these cases could be linked to Helicobacter pylori—a widespread and chronic bacterial infection of the stomach that significantly increases cancer risk. Despite being preventable and treatable, H. pylori remains a major health challenge in many countries. Gastric cancer is currently the fifth most deadly cancer worldwide. The study also points to an anticipated six-fold rise in cases across sub-Saharan Africa, where the current incidence is relatively low. Experts behind the research are urging governments to invest in large-scale preventive measures—especially in screening and treatment programs targeting H. pylori. They stress that such interventions could slash future cancer cases by as much as 75%. The researchers warn that an ageing global population, along with rising cancer rates in younger people, could undo recent progress in cancer control if swift action is not taken. The findings reinforce the urgent need for countries, particularly in Asia, to enhance public health strategies focusing on early diagnosis, education, and bacterial eradication to curb the looming threat of gastric cancer. Source: CNBCTV18

India May Face Over 1.6 Million Gastric Cancer Cases, Global Study Warns Read More »

No Proven Link Between COVID-19 Vaccines and Sudden Deaths, Confirms Union Health Ministry

The Union Ministry of Health and Family Welfare has clarified that there is no scientific evidence connecting COVID-19 vaccination with sudden or unexplained deaths in India. This conclusion is backed by comprehensive studies conducted by the Indian Council of Medical Research (ICMR) and the National Centre for Disease Control (NCDC). In an official statement, the Ministry emphasized that extensive investigations were carried out across the country by multiple research agencies to examine reports of sudden deaths, particularly among seemingly healthy young adults. Findings from these studies have consistently shown no direct association between COVID-19 vaccines and such fatalities. Two key studies have been pivotal in reaching this conclusion. The first, undertaken by ICMR’s National Institute of Epidemiology (NIE), is a multicentric matched case-control study titled “Factors associated with unexplained sudden deaths among adults aged 18–45 years in India.” Conducted across 47 tertiary hospitals in 19 states and union territories from May to August 2023, the research analyzed cases between October 2021 and March 2023. The outcome was clear: COVID-19 vaccination does not increase the risk of sudden death in young, otherwise healthy adults. The second study, still in progress, is being led by AIIMS, New Delhi, with ICMR’s collaboration and support. This prospective research—“Establishing the cause in sudden unexplained deaths in young”—aims to pinpoint the most common reasons behind such fatalities. Preliminary data reveals that heart attacks (myocardial infarctions) remain the leading cause of sudden death in this demographic, with no significant shift in trends compared to previous years. In many cases, genetic factors have also emerged as likely contributors. These studies offer valuable insights into sudden deaths among young individuals and provide reassurance about the safety of COVID-19 vaccines. Researchers highlight that deaths may stem from a range of issues, including underlying health conditions, genetic predispositions, and unhealthy lifestyles, rather than vaccination. Public health experts have strongly criticized unverified claims linking vaccines to sudden deaths, calling them unscientific and dangerous. Such misinformation not only lacks factual basis but also poses a serious risk to public trust and could foster vaccine hesitancy, undermining one of the most effective tools used during the pandemic to save lives. The government reaffirmed its commitment to science-driven public health policies and continued research to safeguard the health and well-being of all citizens. Source: ANI

No Proven Link Between COVID-19 Vaccines and Sudden Deaths, Confirms Union Health Ministry Read More »

Indigenous Kit Developed for Accurate, Rapid Detection of Nipah Virus: ICMR-NIV

In a significant stride for India’s healthcare innovation, the Indian Council of Medical Research (ICMR) has unveiled a homegrown rapid diagnostic kit capable of detecting the Nipah virus with complete accuracy. Designed for swift deployment in the field, the portable test delivers results in just 1 to 2 hours without the need for sophisticated laboratory equipment. Dr. Naveen Kumar, Director of ICMR’s National Institute of Virology (NIV) in Pune, highlighted the effectiveness of the kit, stating, “It is 100% sensitive and specific, relying on the amplification of the viral gene without requiring specialised machinery.” The cost-effective test is priced at ₹250 and is based on the Loop-mediated Isothermal Amplification (LAMP) assay technique. The Nipah virus, a highly lethal zoonotic pathogen with a mortality rate of approximately 50%, is primarily transmitted to humans from fruit bats. It can also spread via contaminated food or human-to-human contact. Symptoms of the infection range from mild flu-like signs to severe respiratory distress and encephalitis, often proving fatal. Recent outbreaks of the disease, particularly the 2023 episode in Kerala’s Kozhikode district, underscore the urgent need for swift and reliable diagnostics. ICMR is concurrently collaborating with Zydus Health Sciences (Ahmedabad) and the Translational Health Science and Technology Institute (Faridabad) on the development of monoclonal antibodies. Efforts are also underway to create an indigenous vaccine for the virus. NIV remains the only laboratory in India equipped to culture the Nipah virus, making it central to the country’s disease surveillance and response capabilities. Source: ANI

Indigenous Kit Developed for Accurate, Rapid Detection of Nipah Virus: ICMR-NIV Read More »